Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2151734
Max Phase: Preclinical
Molecular Formula: C27H37N5O5
Molecular Weight: 511.62
Molecule Type: Protein
Associated Items:
ID: ALA2151734
Max Phase: Preclinical
Molecular Formula: C27H37N5O5
Molecular Weight: 511.62
Molecule Type: Protein
Associated Items:
Canonical SMILES: Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N(C)[C@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N(C)CC(N)=O
Standard InChI: InChI=1S/C27H37N5O5/c1-16-11-20(33)12-17(2)21(16)14-22(28)26(36)32(5)18(3)25(35)30-23(13-19-9-7-6-8-10-19)27(37)31(4)15-24(29)34/h6-12,18,22-23,33H,13-15,28H2,1-5H3,(H2,29,34)(H,30,35)/t18-,22+,23+/m1/s1
Standard InChI Key: UNKNXDWBSNQELQ-LEOXJPRUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 511.62 | Molecular Weight (Monoisotopic): 511.2795 | AlogP: 0.40 | #Rotatable Bonds: 11 |
Polar Surface Area: 159.06 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 4 |
#RO5 Violations: 1 | HBA (Lipinski): 10 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 9.75 | CX Basic pKa: 7.75 | CX LogP: 0.92 | CX LogD: 0.41 |
Aromatic Rings: 2 | Heavy Atoms: 37 | QED Weighted: 0.34 | Np Likeness Score: -0.20 |
1. Vandormael B, Fourla DD, Gramowski-Voss A, Kosson P, Weiss DG, Schröder OH, Lipkowski A, Georgoussi Z, Tourwé D.. (2011) Superpotent [Dmt¹] dermorphin tetrapeptides containing the 4-aminotetrahydro-2-benzazepin-3-one scaffold with mixed μ/δ opioid receptor agonistic properties., 54 (22): [PMID:21978284] [10.1021/jm200894e] |
Source(1):